Jupiter Neurosciences(JUNS.US)

Last Updated 19:00:00 ET
longbridge loading

Jupiter Neurosciences prices registered direct offering at USD 2 million

PUBT·
US
JUNS
-36.88%
PUBT·
US
JUNS
-36.88%

JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1

MSN·
US
JUNS
-36.88%
US
BBH
+0.68%
US
ARKG
+5.01%
MSN·
US
JUNS
-36.88%
US
BBH
+0.68%
US
ARKG
+5.01%

Jupiter Neurosciences shares are trading higher after the company announced it will acquire the U.S. licensing rights to ALA-002 from Pharmala Biotech.

benzinga_article·
US
JUNS
-36.88%
US
IBB
+2.16%
US
BIB
+5.08%
benzinga_article·
US
JUNS
-36.88%
US
IBB
+2.16%
US
BIB
+5.08%

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | JUNS Stock News

StockTitan·
US
JUNS
-36.88%
US
VHT
+0.42%
US
FBT
+1.94%
StockTitan·
US
JUNS
-36.88%
US
VHT
+0.42%
US
FBT
+1.94%

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | JUNS Stock News

StockTitan·
US
JUNS
-36.88%
US
VHT
+0.42%
US
PBE
+1.37%
StockTitan·
US
JUNS
-36.88%
US
VHT
+0.42%
US
PBE
+1.37%
© 2026 Longbridge｜Disclaimer